Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]
Awaiting development
Reference number: GID-TA11639
Expected publication date: TBC
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early July 2026 when we will write to you about how you can get involved.